Revenio Group Corporation: Managers' transactions

Revenio Group Corporation, Managers' transactions, July 27, 2017 at 14:30 EET

Revenio Group Corporation: Managers' transactions

Revenio Group Oyj  - Managers' Transactions
____________________________________________

Person subject to the notification requirement
Name: Karvo Tomi
Position: Other senior manager
(X) Legal person
Issuer: Revenio Group Oyj
LEI: 743700I27E0FWSXLKK04

Notification type: INITIAL NOTIFICATION
Reference number: 743700I27E0FWSXLKK04_20180627120229_5
____________________________________________

Transaction date: 2018-06-25
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
ISIN: FI0009010912
Nature of the transaction: DISPOSAL
(X) Linked to stock option programme


Transaction details
(1): Volume: 100 Unit price: 20.01 EUR

Aggregated transactions
(1): Volume: 100 Volume weighted average price: 20.01 EUR
____________________________________________

Transaction date: 2018-06-25
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
ISIN: FI0009010912
Nature of the transaction: DISPOSAL
(X) Linked to stock option programme


Transaction details
(1): Volume: 100 Unit price: 20 EUR

Aggregated transactions
(1): Volume: 100 Volume weighted average price: 20 EUR
____________________________________________

Transaction date: 2018-06-25
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
ISIN: FI0009010912
Nature of the transaction: DISPOSAL
(X) Linked to stock option programme


Transaction details
(1): Volume: 100 Unit price: 20 EUR

Aggregated transactions
(1): Volume: 100 Volume weighted average price: 20 EUR


For further information, please contact: Robin Pulkkinen, CFO, +358 50 5059932

Distribution:
Nasdaq Helsinki 
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, in which Revenio holds a 53.5% interest. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.

In 2016, Revenio Group's net sales totaled MEUR 23.4, with its operating profit for continuing operations standing at 30.1%. Revenio Group Corporation is listed on Nasdaq Helsinki.

Subscribe